TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25168659
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (high-dose glimepiride)
Study: 19926054
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) plus intravenous sodium bicarbonate (NaHCO3)
Study: 17143601
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg AZD5438
Study: 17143601
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg AZD5438
Study: 24417069
Drug: Ascoril expectorant
Normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascoril expectorant (Glenmark) at a standard dose
Study: 21482606
Drug: Nonsurgical periodontitis
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nonsurgical periodontitis treatment before 21 weeks' gestation
Study: 9568411
Drug: Laceran 10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laceran 10% urea lotion
Study: 9568411
Drug: Urea-free Laceran
Normalized name: Urea
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urea-free Laceran lotion base
Study: 2468300
Drug: Isovolemic hemodilution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isovolemic hemodilution with 500 mL of 10% hydroxyethyl starch 200
Study: 193642
Drug: POCC (procarbazine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: POCC (procarbazine, 100 mg/m2/day orally, Days 1‐14; vincristine, 2 mg iv, Days 1 and 8; cyclophosphamide, 600 mg/m2 iv, Days 1 and 8; and CCNU, 60 mg/m2 orally, Day 1)
Study: 193642
Drug: COM (cyclophosphamide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: COM (cyclophosphamide, 2000 mg/m2 iv, Day 1; vincristine, 2 mg iv, Day 1; and methotrexate, 30 mg/m2 iv, Day 15)
Study: 11798687
Drug: Xuezhikang 1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuezhikang 1.2 g/d Bid, p.o
Study: 11798687
Drug: gemfibrozil 1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemfibrozil 1.2 g/d Bid, p.o
Study: 19304472
Drug: Dual endothelin
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual endothelin receptor antagonists (ERAs)
Study: 19304472
Drug: Selective endothelin
Normalized name: endothelial growth factor A, vascular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective endothelin receptor antagonists (ERAs)
Study: 19304472
Drug: Various endothelin
Normalized name: endothelial growth factor A, vascular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various endothelin receptor antagonists (ERAs)
Study: 7884615
Drug: D-penicillamine therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-penicillamine therapy (20 mg/kg/day)
Study: 1679981
Drug: Albuterol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol (200 micrograms)
Study: 26374625
Drug: Prasugrel 10
Normalized name: prasugrel 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 10 mg maintenance dose
Study: 26374625
Drug: Prasugrel 5
Normalized name: prasugrel 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 5 mg maintenance dose
Study: 12757072
Drug: Fluconazole 600
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole 600 mg/day
Study: 1857478
Drug: Dipyridamole (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole (300 mg/day)
Study: 21349928
Drug: Indacaterol, 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indacaterol, 150 μg once daily
Study: 21349928
Drug: Indacaterol, 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indacaterol, 300 μg once daily
Study: 17898337
Drug: Restoration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restoration of dopamine agonist dosage
Study: 11499564
Drug: Methylprednisolone 1-g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone 1-g i.v. for three days at months 1, 3, and 5, plus oral prednisone (0.5 mg/kg every other day for six months)
Study: 11360502
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g intravenous ceftriaxone once a day (group A)
Study: 11360502
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g intravenous cefotaxime three times a day (group B)
Study: 11360502
Drug: 2.25 g
Normalized name: Zosyn 2.25 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.25 g intravenous cefuroxime three times a day (group C)
Study: 7869314
Drug: sulfasalazine treatment
Normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sulfasalazine treatment
Study: 25810045
Drug: Intralesional corticosteroid
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional corticosteroid therapy repeated every 4 weeks for six sessions (group A)
Study: 23677811
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg ESL (to-be-marketed formulation)
Study: 23677811
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg ESL (to-be-marketed formulation)
Study: 23677811
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg ESL (marketed formulation)
Study: 23677811
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg ESL (marketed formulation)
Study: 21367950
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg Fe + folic acid (IFA)
Study: 21367950
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg Fe + folic acid + 13 micronutrients (UNIMMAP)
Study: 15493566
Drug: Continuous, low-level,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous, low-level, topical heat wrap therapy
Study: 26379122
Drug: Mindfulness-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based cognitive therapy with support to taper and/or discontinue antidepressant medication (MBCT-TS)
Study: 19045965
Drug: Maintenance antidepressant
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance antidepressant medication (m-ADM)
Study: 15179168
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose ATP (225 mg)
Study: 15179168
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose ATP (150 mg)
Study: 11837981
Drug: 3.4 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.4 g/d of highly concentrated very long chain n‐3 PUFA after CABG
Study: 11837981
Drug: Very long
Normalized name: Very long chain fatty acyl-CoA synthase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very long chain n‐3 PUFA 5.1-8.0 g/d after PTCA
Study: 11837981
Drug: 3.4-5.7 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.4-5.7 g/d of very long chain n‐3 PUFA after heart transplantation
Study: 11837981
Drug: 5.1 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.1 g/d of very long chain n‐3 PUFA
Study: 3818036
Drug: Aerua lanata
Normalized name: Krascheninnikovia lanata pollen
DrugBank: Krascheninnikovia lanata pollen (DB10946)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerua lanata extract (200 ml of 50 g/L)
Study: 3818036
Drug: Aerua lanata
Normalized name: Krascheninnikovia lanata pollen
DrugBank: Krascheninnikovia lanata pollen (DB10946)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerua lanata extract (100 g/L)
Study: 26244949
Drug: Enteral paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral paracetamol (15mg/kg/dose 6 hourly for 7 days)
Study: 21340182
Drug: Low-intensity ultrasound
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity ultrasound therapy (LIUST)
Study: 10332320
Drug: Diazepam plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam plus ibuprofen
Study: 8335426
Drug: Pravastatin 20
Normalized name: pravastatin 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 20 mg administered twice daily with meals
Study: 8335426
Drug: Pravastatin 20
Normalized name: pravastatin 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 20 mg administered twice daily one hour before meals
Study: 26429963
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium
Study: 24797294
Drug: Antimicrobial treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial treatment
Study: 21562484
Drug: Pindolol 20
Normalized name: pindolol 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol 20 mg - Placebo
Study: 19447800
Drug: Sivelestat (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sivelestat (0.3 mg/kg/h intravenous)
Study: 12766750
Drug: Intravenous calcium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous calcium chloride, n = 13
Study: 1287557
Drug: Prenatal thyrotropin-releasing
Normalized name: thyrotropin-releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenatal thyrotropin-releasing hormone (TRH) treatment (400 micrograms i.v. every 8 h, one to four doses) plus 12 mg betamethasone (one or two doses)
Study: 1287557
Drug: Prenatal thyrotropin-releasing
Normalized name: thyrotropin-releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenatal thyrotropin-releasing hormone (TRH) treatment
Study: 17683491
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no preparation)
Study: 29533397
Drug: Same-day single
Normalized name: SAMe
DrugBank: Ademetionine (DB00118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same-day single dose of low-volume (SSL) polyethylene glycol (PEG)
Study: 26564575
Drug: Neuromuscular exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuromuscular exercise (NEMEX) program, performed in groups twice weekly for 8 weeks, consisting of 11 exercises focusing on joint stability and neuromuscular control.
Study: 16185242
Drug: Pre-packaging of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-packaging of antimalarial drug
Study: 12363118
Drug: Standardized stepwise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized stepwise drug treatment regimen (SSTR)
Study: 60209
Drug: Initial oral
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial oral dose of 900 mg propafenon
Study: 60209
Drug: Oral dose
Normalized name: Exactamed Oral Dose Syringe 35cc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose of 300 mg propafenon at eight-hourly intervals
Study: 60209
Drug: 1.0-1.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0-1.5 mg propafenon per kg body weight by quick infusion
Study: 30971234
Drug: Holistic physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Holistic physical exercise training intervention once weekly for 15 weeks
Study: 22946673
Drug: Pregabalin with
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin with associated treatments (antidepressants and mood stabilizers)
Study: 19174803
Drug: Radiofrequency thermal
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiofrequency thermal ablation (RF) and Percutaneous ethanol injection (PEI)
Study: 59017
Drug: Human diploid
Normalized name: rabies vaccine, human diploid cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human diploid cell strain rabies vaccine (0.4 ml on day 0)
Study: 59017
Drug: Human diploid
Normalized name: rabies vaccine, human diploid cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human diploid cell strain rabies vaccine (0‐1 ml on days 0, 3, 7, and 14)
Study: 59017
Drug: Human diploid
Normalized name: rabies vaccine, human diploid cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human diploid cell strain rabies vaccine (0.1 ml into each limb on day 0)
Study: 17178485
Drug: Methylprednisolone 1
Normalized name: methylprednisolone 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone 1 mg/kg
Study: 11791892
Drug: FP-spacer: fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: FP-spacer: fluticasone pressurised metered dose inhaler (Flixotide 250 microg ex-valve per actuation), eight puffs via a primed Volumatic 750-ml spacer.
Study: 11791892
Drug: FP-neb: Flixotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: FP-neb: Flixotide Nebule 2 mg/2 ml via Pari LC Plus nebuliser.
Study: 9230825
Drug: Latanoprost and
Normalized name: latanoprost and netarsudil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latanoprost and Physostigmine combination
Study: 1773364
Drug: Bolus injection
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus injection of alfentanil
Study: 25544263
Drug: sugammadex 2
Normalized name: sugammadex 200 MG in 2 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: sugammadex 2 mg/kg
Study: 29025888
Drug: Erdosteine 300
Normalized name: erdosteine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erdosteine 300 mg twice daily
Study: 25410076
Drug: Salmon calcitonin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmon calcitonin, 50 IU, subcutaneous injection, 1 time a day for 15 days
Study: 25410076
Drug: Salmon calcitonin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmon calcitonin, 50 IU, subcutaneous injection, 1 time every 3 days for 90 days
Study: 25410076
Drug: Salmon calcitonin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmon calcitonin, 50 IU, subcutaneous injection, 1 time every 2 days for 30 days
Study: 7597269
Drug: Bronchodilator therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bronchodilator therapy
Study: 16167973
Drug: 2.2 g
Normalized name: Vaporizer Safeguard 2.2 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.2 g co-amoxiclav (or 2 g cefotaxime if penicillin-allergic)
Study: 12207636
Drug: Selective serotonin
Normalized name: Selective serotonin (5HT1) agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective serotonin reuptake inhibitors (SSRI)
Study: 10334546
Drug: Oral F‐AMP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral F‐AMP 50 mg
Study: 10334546
Drug: Oral F‐AMP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral F‐AMP 70 mg
Study: 2409845
Drug: Lactated Ringer's
Normalized name: LACTATED RINGER'S
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactated Ringer's solution (group C)
Study: 30595274
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment without any supervised exercise intervention
Study: 22323895
Drug: Niacin extended-release/simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niacin extended-release/simvastatin (NER/S)
Study: 19804455
Drug: Intermediate-dose cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intermediate-dose cytarabine for 4 days followed by gemtuzumab ozogamicin on day 5 (Arm A)
Study: 19804455
Drug: Intermediate-dose cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intermediate-dose cytarabine for 4 days combined with liposomal daunorubicin for 3 days (Arm B)
Study: 17561795
Drug: Once-daily glargine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily glargine (GL)
Study: 17561795
Drug: Twice-daily 70/30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-daily 70/30 aspart premix
Study: 27112607
Drug: Reperfusion therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reperfusion therapy
Study: 16082602
Drug: Not receiving
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not receiving reperfusion therapy
Study: 10456206
Drug: Insulin tolerance
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin tolerance test in the morning (0830 h)
Study: 10456206
Drug: Insulin tolerance
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin tolerance test in the evening (2030 h)
Study: 10456206
Drug: NEFA response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: NEFA response to insulin in the morning
Study: 10456206
Drug: NEFA response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: NEFA response to insulin in the evening
Study: 8642805
Drug: rilmenidine (1‐2
Approvals — FDA: no, EMA: no, PMDA: no
Description: rilmenidine (1‐2 mg/day)
Study: 8960851
Drug: atenolol (50‐100
Approvals — FDA: no, EMA: no, PMDA: no
Description: atenolol (50‐100 mg/day)
Study: 21047568
Drug: Fluvastatin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin (3 times 40 mg at 0 hr, 24 hr, and 48 hr)
Study: 21047568
Drug: Fluvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin (40 mg at 0 hr) plus placebo (24 hr and 48 hr)
Study: 15848261
Drug: Therapy combined
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy combined with standing balance training by biofeedback (BPM Monitor)
Study: 12585949
Drug: Carvedilol (3.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (3.125 mg twice daily, uptitrated to 25 mg twice daily)
Study: 10565463
Drug: CSF glycine
Normalized name: Glycine
DrugBank: Glycine (DB00145)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CSF glycine levels in newborns without HIE (12.49 micromol/l)
Study: 16119597
Drug: morphine 1
Normalized name: morphine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine 1 mg
Study: 28449402
Drug: lixisenatide 20
Normalized name: lixisenatide 20 mcg/0.2 mL subcutaneous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: lixisenatide 20 µg
Study: 28449402
Drug: insulin-glulisine (iGlu)
Approvals — FDA: no, EMA: no, PMDA: no
Description: insulin-glulisine (iGlu)
Study: 23870608
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination of ASA 100 mg and clopidogrel 75 mg
Study: 23870608
Drug: Free combination
Normalized name: SUNSCREEN-29 PABA-FREE COMBINATION LOT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free combination of ASA and clopidogrel
Study: 23870608
Drug: Both formulations
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both formulations (fixed-dose and free combination)
Study: 21898310
Drug: Preventive intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive intervention programme (watchful waiting, bibliotherapy, problem-solving treatment, re-referral to primary care)
Study: 17898401
Drug: Gabapentin plus
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin plus dexamethasone (800 mg gabapentin and 8 mg dexamethasone IV)
Study: 18840107
Drug: Gabapentin (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (800 mg)
Study: 11533837
Drug: 8 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg/kg per day of oral iron
Study: 11533837
Drug: 16 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg/kg per day of oral iron
Study: 11533837
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of both doses (8 mg/kg vs 16 mg/kg)
Study: 9934543
Drug: Cefotaxime 50
Normalized name: cefotaxime 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime 50 mg/kg twice-daily (n = 130)
Study: 9934543
Drug: Cefotaxime 33.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime 33.3 mg/kg three-times-daily (n = 128)
Study: 8109809
Drug: Salbutamol delivered
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol delivered from a metered dose inhaler (MDI)
Study: 25946929
Drug: 100,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100,000 IU of oral vitamin D per month for 6 months
Study: 11535498
Drug: Myeloablative SCT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myeloablative SCT (cyclophosphamide/high-dose total body irradiation)
Study: 9573752
Drug: Gonadotropin‐Releasing Hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gonadotropin‐Releasing Hormone analogue (two injections monthly)
Study: 2899773
Drug: Sodium fluoride
Normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium fluoride 25 mg twice daily plus elemental calcium 1 g daily and a vitamin D2 supplement
Study: 11986206
Drug: Standard cytarabine-based
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard cytarabine-based therapy
Study: 9719109
Drug: External radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: External radiation therapy plus temporary stereotactic iodine-125 implants delivering a minimum peripheral tumor dose of 60 Gy
Study: 9719109
Drug: External radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: External radiation therapy only delivering 50 Gray (Gy) in 25 fractions over 5 weeks
Study: 8083913
Drug: Sequential gradient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential gradient pneumatic leg compression (SCD)
Study: 17181922
Drug: Interferential currents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferential currents (IFT) administered for 10 minutes daily for 5 days per week for two weeks
Study: 17181922
Drug: Horizontal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Horizontal therapy (HT) administered for 40 minutes daily for 5 days per week for two weeks
Study: 8738112
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplementation (FO, 22 ml daily, containing 4.6 g of n‐3 fatty acids)
Study: 8738112
Drug: Gemfibrozil (G,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemfibrozil (G, 900 mg daily)
Study: 8738112
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplementation (FO, 22 ml daily)
Study: 1568520
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg O‐(beta‐hydroxyethyl)rutosides orally twice daily
Study: 18520448
Drug: Pentavalent rotavirus
Normalized name: Vaccine product containing only live pentavalent Rotavirus antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentavalent rotavirus vaccine (live, oral)
Study: 10963018
Drug: Metaphonologically (MET)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metaphonologically (MET) therapy
Study: 10963018
Drug: Articulation‐based (ART)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Articulation‐based (ART) therapy